A Phase 3 interventional study of Ketofol and propofol (drug) in The Critically Ill Patient is Requiring Intubation, Septic Shock and Pneumonia, sponsored by Helwan University. Active, not recruiting at 1 site in Egypt. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Helwan University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Shock, Septic with a site in Egypt — 16 open to participants now, 17 under way, 1 of them phase 3. Shock, Septic · Egypt.
Among the 61 studies in Shock, Septic with a site in Egypt, this one is the 14th largest by planned enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2026, is one of 9 in phase 3, reaches primary completion later than 6 of the 16 other live ones, and was the 53rd registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →16 of the 61 studies in Shock, Septic with a site in Egypt are open now. Recruiting first, the newest first:
Menoufia University · Sites in Egypt
Ages 18+
Menoufia University · Sites in Egypt
Ages 1 mo–18 yrs
Alexandria University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 18–50
Ain Shams University · Sites in Egypt
Ages 1 mo–16 yrs · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 11 · Phase 4 7
First in 2016; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 60 across the 37 interventional studies, 65 across the 24 observational. Of the 32 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 61 have an industry lead sponsor. The 10 most frequent:
Helwan University is the lead sponsor of 70 studies on the registry; 15 are open to participants now.
Helwan University has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
5 of the studies in Shock, Septic with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07245550Assiut UniversityThyroid and Adrenal Disorders in ICU | 2026-12-01 |
| NCT07516236Menoufia UniversityDynamic SvO2 in Predicting Fluid Responsiveness in Septic Shock | 2027-01 |
| NCT07706413Menoufia UniversityPlasma Exchange in Children With Severe Sepsis and Septic Shock | 2027-02-28 |
| NCT07716956Alexandria UniversityEffect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients | 2027-04 |
| NCT07321405Assiut UniversityAssessment of Cardiac Output and Stroke Volume in Septic Shock Patients | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Shock, Septic with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a prospective randomized controlled trial comparing the efficacy and safety of propofol-ketamine ("Ketofol") versus propofol monotherapy in geriatric ICU patients. Eligible participants are critically ill elderly patients with a history of cardiac disease who require endotracheal intubation and have not yet received sedation. The investigators focus on a specific population in which geriatric patients have different pharmacokinetics and pharmacodynamics and are more prone to side effects than other populations.
Primary outcome: Incidence of hemodynamic instability (defined as hypotension requiring vasopressors), measured by mean arterial pressure (MAP) 5 minutes after induction
Secondary outcomes include changes in blood pressure and heart rate, incidence of hypotension, vasopressor requirements, sedation depth, pain scores, cumulative sedative and opioid consumption, adverse events, ICU length of stay, and ICU mortality at predefined intervals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will take bolus dose of Propofol 0.25 mg/kg + Ketamine 0.25mg/kg If patient NOT sedated and need additional doses will be given another Propofol 0.25 mg/kg + Ketamine 0.25mg/kg IV
Drug: Ketofol
Patients will take Propofol lowest bolus dose of 0.5 mg/kg IV as monotherapy. If patient NOT sedated and need additional doses will be given another dose of 0.25 to 0.5 mg/kg after hemodynamically assessment
Drug: propofol (drug)
Patients will take bolus dose of Propofol 0.25 mg/kg + Ketamine 0.25mg/kg If patient NOT sedated and need additional doses will be given another Propofol 0.25 mg/kg + Ketamine 0.25mg/kg IV
Propofol given normal doses for intubation but at reduced and gradual dosing regimen regarding geriatric patient
Mean arterial pressure (MAP, mmHg) at 5 minutes
Mean arterial pressure (MAP, mmHg) at 5 minutes after administration of the induction agent
Time frame: 5 minutes post induction
Vasopressor escalation within 5 minutes
Time frame: 5 minutes
Peak norepinephrine dose within 5 minutes
Time frame: 5 minutes
Systolic blood pressure at 5 minutes after induction
Systolic blood pressure measured in mmHg
Time frame: 5 minutes after induction
Diastolic blood pressure at 5 minutes after induction
Diastolic blood pressure measured in mmHg
Time frame: 5 minutes after induction
Incidence of hypotension
Time frame: Post-induction period
Pain intensity score
using CPOT score
Time frame: within 24h
Sedation depth (RASS score)
Time frame: From 30 minutes to 24 hours
Cumulative fentanyl consumption
Time frame: During the study observation period
Adverse events
Incidence of Adverse events
Time frame: During ICU follow-up
All-cause ICU mortality
Time frame: During ICU stay
Plan to share: Undecided
Ran from May 2026 to primary completion in Sep 2026, 4 months.
Of 45 non-industry phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's 4 months is below that.
Counting every sponsor, half of 46 studies reached it within 42 months; a quarter within 16 and three quarters within 59.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Sep 2026, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ketofol · Propofol
Helwan University